|
 |
 |
December 2004 |
| Newsletter | ||
SOLVO Biotechnology is happy to announce that, as a result of our recent development efforts, we have expanded our portfolio with three new products: human BSEP membrane vesicles, upgraded MRP2-VT protocols, and new control vesicles for studies on Sf9 membrane preparations.
The bile salt export pump (BSEP) belongs to the family of ATP-binding-cassette transporters and has also been called the sister of P-glycoprotein (Childs et al, 1995). BSEP is the major bile salt transporter in the liver canalicular membrane and it is inhibited by a number of therapeutic drugs, drug metabolites (Funk et al. 2001). This is a potentially significant mechanism for drug-induced cholestasis (Byrne et al, 2002). Dysfunction of individual bile salt transporters such as BSEP, on account of genetic mutations, steric inhibition, suppression of gene expression, or disturbed signaling, is an important cause of cholestatic liver disease (Kullak-Ublick et al, 2004).
We recently upgraded our MRP2 Vesicular Transport assay. From now on, we propose β-estradiol-glucuronate as transported substrate in this assay. This active transport by MRP2 is inhibited by interacting compounds at high β-estradiol-glucuronate concentrations. At low β-estradiol-glucuronate concentrations, transport is significantly stimulated by co-transported substrates (e.g. furosemide, indomethacin, sulfinpyrazone, etc.). We strongly recommend to use β-estradiol-glucuronate, however, LTC4 is still and option. A new version of the LTC4 vesicular transport system is also available (v. 1.3.). This new LTC4 assay provides lower background transporter activity and greater dynamic range compared to the previous version. For further information please visit our website.
Solvo Biotechnology has introduced a new Sf9 control membrane preparation especially for vesicular transport studies. These vesicles contain a defective mutant of the MRP1 protein. This new control membrane preparation provide several advantages compared to the earlier betaGal-expressing vesicles. Since the defMRP1 protein is processed by the Sf9 cell protein synthesis and targeting machinery in a very similar fashion to other active ABC transporters, this preparation provides a more precise control for vesicular transport and ATPase assays.
We attached our recently updated product catalog for your review. If you have any questions, please feel free to let me know. We hope to hear from you at your earliest convenience.
|
For Customers in Japan:
Funakoshi (distributor of SOLVO membrane products)
Iwaki (exclusive distributor of SOLVO Fee-for Service Screenings, distributor of SOLVO membrane products)
|
| Privileged/confidential information may be contained in this message. This communication is confidential and intended solely for the addressee(s). Unauthorized distribution, modification or disclosure of the contents may be unlawful. If you receive this in error, please notify the sender and delete it from your system. If you are not the addressee indicated in this message (or responsible for delivery of the message to such person), you may not copy or deliver this message to anyone. |
If you wish to
unsubscribe, please send a letter to 
with 'unsubscribe' in the subject field. |